Clinical Trials and Cerebrospinal Fluid (CSF) Monitoring

brain 3.jpg

The Koschmann lab is applying a novel precision medicine approach accounting for both unique tumor biology and optimization of blood brain barrier penetration.  We are performing correlate biology work on ongoing precision medicine trials for children and young adults with brain tumors at the University of Michigan, including correlation of spinal fluid analysis with surveillance MRIs.

Dual therapy with mTOR inhibitors to improve precision medicine therapy delivery

Recent work has documented the mutation, amplification and up-regulation of PDGFRA in a significant subset of pediatric patients with high-grade glioma (HGG) (Koschmann et al, Oncotarget, 2016).  There are multiple orally bioavailable tyrosine kinase inhibitors (TKIs) with published safety data in pediatric cancers. Many TKIs display favorable characteristics for BBB penetration (small size, high lipophilicity), but are substrates for the active efflux proteins P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), which significantly limits their brain penetration.Recent pre-clinical strategies have included co-administration of TKIs with agents that inhibit these proteins, including mammalian target of rapamycin (mTOR) inhibitors.  Everolimus displays active Bcrp1 and P-gp inhibition, which has been shown to improve brain parenchymal penetration of TKIs.

Dr. Carl Koschmann is the Principal Investigator of an ongoing clinical phase 2 trial that incorporates the use of dasatinib and everolimus for children with high-grade glioma and diffuse intrinsic pontine glioma (DIPG) (NCT03352427).  As well, the Koschmann Lab is exploring the concept of improving targeted TKI delivery to brain tumors through in vitro and in vivo work in the Koschmann lab.


Spinal fluid for the diagnosis and treatment monitoring of precision medicine therapies:

Obtaining a tissue sample from children with DIPG and other “midline” high-risk tumors carries significant risk as neurological injury can occur as a result of biopsies. With the aid of the cutting-edge technology, we are developing a new method to instead test a tumor’s growth markers through cerebrospinal fluid (CSF) and blood samples. A safer and less invasive method, this method provides faster recovery and more accurate monitoring of children with high-risk pediatric brain tumors and their responses to targeted therapies.  Increasingly, Dr Koschmann and his team are including spinal fluid analysis with surveillance MRIs for children on targeted therapies, including multiple clinical trials active at the University of Michigan.  Ongoing work in the Koschmann lab is looking at the DNA and RNA landscape of spinal fluid to uncover new metrics for diagnosis, prognosis and therapeutic response.

preicision medicine project - cost estimate EEG edits .jpg